SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended ...
Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.
We are actively planning a phase II clinical trial of PRX-115 in gout patients and expect to initiate the study in the second half of 2025." Third Quarter 2024 and Recent Business Highlights Pipeline ...